Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19

NCT05387239 is registered in ClinicalTrials.gov with Vitti Labs, LLC as lead sponsor.

NCT NCT05387239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05387239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19
Lead sponsor
Vitti Labs, LLC
Phase
Phase 2
Overall status
Suspended
Start date
November 30, 2022
Completion date
December 31, 2024
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 respiratory infection, pulmonary fibrosis